Researchers From New York Presbyterian Hospital Discuss Findings In Lymphoma Therapy

New investigation results, 'Management of relapsed mantle cell lymphoma: still a treatment challenge,' are detailed in a study published in ONCOLOGY. "Mantle cell lymphoma (MCL) is a distinct subtype of non-Hodgkin lymphoma that remains incurable, and is associated with a median survival of approximately 5 years. Management of patients with relapsed or refractory disease is challenging," investigators in the United States report. "The major therapeutic goal in MCL management is to improve survival and quality of life whenever possible. Progress has been made in MCL therapy in the past decade based on clinical experimentation with novel agents and combinations. There is a growing list of conventional and novel agents in our armamentarium,...